机构：[1]The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200433, China [2]Department of Oncology, Shanghai Tongren Hospital, Shanghai Jiaotong University, Shanghai 200336, China [3]Department of Urology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China [4]Department of Computer Science, Rensselaer Polytechnic Institute, Troy, NY, 12180, United States of America [5]Department of Microbiology, Shanghai Key Laboratory of Medical Biodefense, Second Military Medical University, Shanghai 200433, China [6]The Fourth Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200433, China
Aberrant chromobox (CBX) family protein expression has been reported in a variety of human malignancies. However, the role of CBX6 in hepatocellular carcinoma (HCC) progression and patient prognosis remains unknown. In this study, we found that CBX6 was frequently up-regulated in HCC clinical samples and HCC cell lines and that CBX6 expression was significantly correlated with larger tumor sizes (>= 5 cm, p = 0.011) and multiple tumors (n >= 2, p = 0.018). Survival analyses indicated that patients with higher CBX6 expression levels had significantly shorter recurrence-free survival (RFS) and overall survival (OS) than patients with lower CBX6 expression levels, and multivariate analyses confirmed that increased CBX6 expression was an independent unfavorable prognostic factor for HCC patients. Functional study demonstrated that CBX6 profoundly promoted HCC cell growth both in vitro and in vivo, and mechanistic investigation revealed that the S100A9/NF-kappa B/MAPK pathway was essential for mediating CBX6 function. In conclusion, our results represent the first evidence that CBX6 contributes to tumor progression and indicate that the protein may serve as a novel prognostic biomarker for HCC and as a therapeutic target in the treatment of the disease.
基金：
National Key Basic Research Program of China (2014CB542102);the Science Fund for Creative Research Groups, NSFC, China (81221061); the National Natural Science Foundation of China (81672335);the State Key Infectious Disease Project of China (2012ZX10002010); and the Shanghai New Excellent Youth Plan (XYQ2013074). National Key Basic Research Program of China (2014CB542102);the Science Fund for Creative Research Groups, NSFC, China (81221061); the National Natural Science Foundation of China (81672335);the State Key Infectious Disease Project of China (2012ZX10002010); and the Shanghai New Excellent Youth Plan (XYQ2013074).
第一作者机构：[1]The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200433, China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Hao Zheng,Wei-hua Jiang,Tao Tian,et al.CBX6 overexpression contributes to tumor progression and is predictive of a poor prognosis in hepatocellular carcinoma[J].ONCOTARGET.2017,8(12):18872-18884.
APA：
Hao Zheng,Wei-hua Jiang,Tao Tian,Hai-song Tan,Ying Chen...&Wei-ping Zhou.(2017).CBX6 overexpression contributes to tumor progression and is predictive of a poor prognosis in hepatocellular carcinoma.ONCOTARGET,8,(12)
MLA：
Hao Zheng,et al."CBX6 overexpression contributes to tumor progression and is predictive of a poor prognosis in hepatocellular carcinoma".ONCOTARGET 8..12(2017):18872-18884
医学